The human mixed lineage leukemia (MLL) gene is frequently involved in genetic rearrangements with more than 55 different translocation partner genes, all associated with acute leukemia. Reciprocal chromosomal translocations generate two MLL fusion alleles, where 5 0 -and 3 0 -portions of MLL are fused to gene segments of given fusion partners. In case of t(4;11) patients, about 80% of all patients exhibit both reciprocal fusion alleles, MLL . AF4 and AF4 Á MLL, respectively. By contrast, 20% of all t(4;11) patients seem to encode only the MLL Á AF4 fusion allele. Here, we analyzed these 'MLL Á AF4 þ /AF4 Á MLL À ' patients at the genomic DNA level to unravel their genetic situation. Cryptic translocations and three-way translocations were found in this group of t(4;11) patients. Reciprocal MLL fusions with novel translocation partner genes, for example NF-KB1 and RABGAP1L, were identified and actively transcribed in leukemic cells. In other patients, the reciprocal 3 0 -MLL gene segment was fused out-of-frame to PBX1, ELF2, DSCAML1 and FXYD6. The latter rearrangements caused haploinsufficiency of genes that are normally expressed in hematopoietic cells. Finally, patients were identified that encode only solitary 3 0 -MLL gene segments on the reciprocal allele. Based on these data, we propose that all t(4;11) patients exhibit reciprocal MLL alleles, but due to the individual recombination events, provide different pathological disease mechanisms.
Introduction
Chromosomal translocations of the human mixed lineage leukemia (MLL) gene are associated with infant, childhood, adult and therapy-related acute lymphoblastic or myeloid leukemias (ALL and AML). 1, 2 The molecular pathology of different MLL translocations has been assigned to the presence of the der(11)-allele, 3 which encodes the N-terminal portion of MLL fused to one of the 55 different translocation partner genes. 4, 5 Molecular analyses revealed a direct link between the presence of der(11)-encoded MLL fusion proteins and the deregulation of certain genes of the HOXA cluster. [6] [7] [8] In particular, the deregulated transcription of HOXA7 and HOXA9, in conjunction with the upregulation of MEIS1, appears to be sufficient to immortalize myeloid progenitors by turning them into a rapidly proliferating population of preleukemic cells. Over time, this cell population may acquire secondary mutations finally resulting in a malignant leukemia phenotype. [9] [10] [11] Genes found to be affected by the der(11)-encoded MLL fusion proteins are specific HOX genes, 6 the MYB gene 12 and certain cyclin kinase inhibitors. 13, 14 In several studies, direct binding of the der(11)-encoded MLL fusion protein to promoter regions of the above-mentioned genes has been demonstrated by ChIP (chromatin immunoprecipitation) experiments). 13, [15] [16] [17] This indicates that MLL fusion proteins encoded by the der (11) chromosome are able to influence directly the transcription of specific target genes.
Transgenic mice or the genetic manipulation of murine hematopoietic stem/precursor cells by retroviral transduction and subsequent transplantation into syngenic mice has demonstrated successfully that the overexpression of certain der(11)-encoded MLL fusion proteins is sufficient and necessary for the onset of acute myeloid leukemia. This concept has been tested for MLL Á AF9, MLL Á ENL, MLL Á ELL, MLL Á GAS7, MLL Á CBP and MLL Á AF10. All of them showed malignant transformation of myeloid precursors and developed a leukemic disease in mouse models. 6, [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] By contrast, some der(11)-encoded MLL fusions (MLL Á ABI1, MLL Á AF4, MLL Á FBP17, MLL Á GRAF and MLL Á LASP1) failed to form immortalized colonies in semi-solid agar or engraftment in recipient mice. 31 Thus, their malignant potential could not be investigated. Reasons to explain the failure of these fusion constructs to induce a leukemic disease in the mouse models are presumably complex, including differences between mouse and human proteins, missing mutations in recipient cells, or simply culture conditions used for the manipulated hematopoietic murine stem cells. Another possibility could be that these negatively tested MLL fusion proteins require a specific 'permissive cell type' to provide their malignant potential or their inability to be 'genetically instructive'.
An exception is the recently characterized MLL Á AF4 fusion protein. By using the inverter mouse model in conjunction with cell-type specifically expressed Cre-recombinase, the MLL Á AF4 fusion protein was able to instruct genetically lymphocytic progenitors and early T-cells to develop only into the Blineage. 32 Although genetically instructive, the MLL Á AF4 fusion protein was not able to cause an acute leukemia rather than a lymphoma disease phenotype.
Here, we want to draw attention to the possibility that t(4;11) leukemia is mediated not only by the presence of the MLL Á AF4 fusion protein, but by the presence of both reciprocal MLL fusion proteins. It has already been demonstrated that the MLL Á AF4 fusion gene alone is not sufficient to form immortalized colonies in semi-solid agar (So et al., Blood 2004; 104: 467 abstract) . Both the Mll Á Af4 knock-in and the Mll Á Af4 inverter mouse developed a B-cell lymphoma with low penetrance (50% developed the B-cell lymphoma after a median time of 540 days, which is more than two-thirds of the natural lifespan of a mouse). 32, 33 By contrast, the reciprocal AF4 Á MLL fusion protein was able to growth transform murine fibroblasts in classical focus formation assays. 34 Moreover, cotransfected cells expressing both the MLL Á AF4 and AF4 Á MLL fusion protein were shown to have a selective advantage over single-transfected cells with respect to cell cycling, cell growth, apoptotic behavior and growth transformation.
14 These data demonstrated that both reciprocal MLL fusion proteins in t(4;11) leukemia are syngergistically contributing to the leukemia disease phenotype.
However, about 20% of investigated t(4;11) patients seem to encode only the der(11) allele. The reciprocal AF4 Á MLL fusion allele can neither be identified at the RNA nor at the genomic DNA level by using direct long-range polymerase chain reaction (PCR) experiments. 35, 36 This has led to the conclusion that the reciprocal AF4 Á MLL fusion allele could not have any biological importance, because otherwise it would be present in all t(4;11) patients.
The controversial situation between genotypes and functional data prompted us to investigate the genetic situation in t(4;11) leukemia patients in more detail. For this purpose we investigated a subgroup of t(4;11) patients, which were identified by reverse transcriptase-(RT)PCR analyses as MLL Á AF4 þ /AF4 Á MLL À patients. Assuming that the selection process relies only on the presence of a functional der(11) fusion allele, reciprocal MLL fusion alleles should not be present in any of these patients. However, if reciprocal MLL fusion alleles have any importance or contribute to the leukemogenic process, we should be able to identify such reciprocal alleles.
Ten out of 13 investigated MLL Á AF4 þ /AF4 Á MLL À patients were successfully analyzed. All MLL Á AF4 þ /AF4 Á MLL À patients encode either in-frame reciprocal MLL fusions, out-of-frame reciprocal MLL fusions or solitary 3 0 -MLL gene segments. These 5 0 truncated MLL gene segments, however, are still able to express the recently identified MLL* transcript and the MLL* protein. 37 Therefore, all analyzed MLL Á AF4 þ /AF4 Á MLL À patients are per se able to express the C-terminal portion of the MLL protein.
Materials and methods

Patient data
Biopsy material of 76 t(4;11) patients with de novo ALL disease phenotype was obtained within the framework of the I-BFM, Interfant-99 and GMALL study group. Residual material from diagnostic procedures was used. Genomic DNA was isolated from bone marrow and/or peripheral blood samples and sent to the Diagnostic Center of Acute Leukemia (DCAL, Frankfurt). Informed consent was obtained from all patients, parents or legal guardians and control individuals.
Long distance inverse PCR experiments
All DNA samples were treated and analyzed as described. 38 Briefly, 1 mg genomic patient DNA was digested with appropriate restriction enzymes and religated to form DNA circles before LDI-PCR analyses. Restriction polymorphic PCR amplimers were isolated from the gel and subjected to DNA sequence analysis to obtain the patient-specific fusion sequences. After cloning the MLL Á AF4 fusion allele, all subsequent fusion alleles were cloned step by step by using reciprocal LDI-PCR or LR-PCR approaches to identify and clone the proposed AF4 Á X and X Á MLL fusion alleles (X represents a recombined allele). By applying this systematic approach, the genetic situation in 10 out of 13 MLL Á AF4 þ /AF4 Á MLL À patients (P03-159, P03-175, P03-178, P03-187, P03-217, P03-231, P04-268, P04-275, P05-403, P05-442) was determined. Oligonucleotide sequences will be made available upon request.
RNA preparation, cDNA synthesis and RT-PCR experiments
RNA was isolated from cryopreserved MNC using the RNeasy Mini Kit (Qiagen Hilden, Germany) according to the manufacturer's recommendations. RNA was reverse-transcribed with 200 units of M-MLV reverse transcriptase (Invitrogen, Karlsruhe, Germany) and 100 pmol random hexamers at 421C for 1 h. RT-PCR experiments were performed using standard conditions using oligonucleotides specific for a large variety of genes tested in this study. 5 0 -and 3 0 -RACE experiments were performed by using the GeneRacer Kit (Invitrogen) according to the recommendations of the manufacturer. Oligonucleotide sequences will be made available upon request.
Results
Identification of reciprocal MLL fusion alleles in MLL
Acute leukemia patients carrying t(4;11) translocations were pre-screened by RT-PCR and split-signal FISH experiments. [39] [40] [41] [42] Genomic DNA of 76 patients were subjected to the recently developed long-distance inverse (LDI)-PCR method to clone MLL fusion alleles. 38 In all cases, the genomic fusion site between the MLL gene and the AF4 gene was identified. By using the reciprocal LDI-PCR approach, only 63 patients displayed an AF4 Á MLL fusion allele (83%) while 13 patients remained negative (17%). A direct genomic long range-PCR (LR-PCR) approach, 36 testing for unusual rearrangements including larger deletions, inversions or duplications, remained also negative for reciprocal AF4 Á MLL fusion alleles. Therefore, the reciprocal LDI-PCR experiments were modified by using new combinations of restriction enzymes and oligonucleotides, including AF4-and MLL-specific oligonucleotides. This approach led to the identification of reciprocal alleles in 10 out of 13 MLL Á AF4 þ /AF4 Á MLL À patients. By using the novel sequence information, direct genomic PCR experiments were conducted by using oligonucleotides specific for the reciprocal alleles in combination with MLL-or AF4-specific oligonucleotides. All genomic PCR amplimers were sequenced to identify the precise genomic fusion sites and to reconstruct the complex recombination mechanisms. Thus, the genetic situation in each of these 10 patients was determined. All recombination events disrupted the AF4 and the MLL gene in their breakpoint cluster regions. Therefore, we termed the translocated gene segments as 5 0 -MLL (exons1-9/10/11), 3 0 -MLL (exons10/11/12-37), 5 0 -AF4 (exons 1-3) and 3 0 -AF4 gene segment (exons4-20) to explain the unusual gene fusions described below.
Reciprocal gene fusions of the MLL and AF4 gene
Six out of 10 MLL Á AF4 þ /AF4 Á MLL À patients exhibited reciprocal gene fusions (see Figure 1) . Patient P03-159 displayed a 3-way-translocation involving chromosomes 1, 4 and 11, t(4;11) genetics E Kowarz et al respectively. The resulting derivative chromosomes der(1), der(4) and der(11) were coding for a PBX1 Á MLL fusion gene, an AF4 Á PBX1 fusion gene and an MLL Á AF4 fusion gene (intron11Hintron3), respectively. The recombination sites within the PBX1 Á MLL (intron1Hinton12) and AF4 Á PBX1 fusion genes (intron3Hintron1) disrupted per se the open reading frames. We cannot exclude that alternative splice processes (skipping of single exons) may lead to in-frame fusions, however, no mRNA of this patient was available to test this possibility.
Patient P03-178 represents a reciprocal translocation in combination with a deletion of chromosome 4 sequences (0.1 Mbp). The der(11) chromosome displayed the MLL Á AF4 fusion (intron9Hintron3). The genomic fusion site on the der(4) chromosome was identified 20.724 bp downstream of AF4 
0 -RACE experiments revealed that the AF4 exons1a1 and 1a2 are spliced to MLL exon10. However, the resulting fusion mRNA is out-of-frame.
Patient P03-217 carries an insertion of chromosome 4 material (15.5 Mbp) into the MLL gene. This led to two fusion sites on the resulting der(11) chromosome. At the centromeric fusion site the MLL Á AF4 fusion gene (intron10Hintron3) was identified, while the telomeric fusion site encodes an NFkB1 Á MLL fusion gene (intron23Hintron10). On the der(4) chromosome, an AF4 Á NFkB1 fusion gene was identified (intron3Hintron23). All three fusion genes represent in-frame fusions and are expressed in the patient (Figure 2a) .
Patient P03-231 carries an insertion of chromosome 11 material (0.6 Mbp) into the AF4 gene. This led to two fusion sites on the resulting der(4) chromosome. At the centromeric fusion site, the AF4 gene was fused 'tail-to-tail' to the FXYD6 gene (intron3Hintron1), while the telomeric fusion site encodes the MLL Á AF4 fusion gene (intron10Hintron3). The transcriptional orientation of the AF4 and the FXYD6 gene is in opposite direction, and thus, neither an AF4 nor an FXYD6 fusion product could be produced. The der(11) chromosome exhibits a 3 0 -FXYD6 gene segment fused 'head-to-head' with the remaining 3 0 -MLL gene segment (intron1Hintron10). Patient P04-268 carries an insertion of chromosome 4 material (52 Mbp) into the MLL gene. This led to two fusion sites on the resulting der(11) chromosome. At the centromeric fusion site, the MLL Á AF4 fusion gene was identified (intron11Hintron3), while the telomeric recombination site encodes the 3 0 -ELF2 gene segment fused 'head-to-head' to the 3 0 -MLL gene segment (intron3Hintron11). On the der(4) chromosome, a 'tail-to-tail' fusion between a 3 0 -truncated AF4 gene segment and the 3 0 -truncated ELF2 gene segment was observed (intron3Hintron3). Again, the transcriptional orientation of the truncated ELF2 gene is in opposite orientation with regard to the AF4 and MLL gene, and thus, neither a functional ELF2 Á MLL nor a functional AF4 Á ELF2 fusion product could be produced.
Patient P05-403 carries an insertion of chromosome 11 material (1 Mbp) into the AF4 gene. This led to two fusion sites on the resulting der(4) chromosome. At the centromeric fusion site, the 5 0 -AF4 gene segment was fused 'tail-to-tail' with the 5 0 -DSCAML1 gene segment (intron3Hintron16), while the telomeric fusion site encodes the MLL Á AF4 fusion gene (intron12Hintron3). On the der(11) chromosome, the 3 0 -DSCAML1 gene segment was fused 'head-to-head' with the 3 0 -MLL gene segment (intron16, intron12). However, 5 0 -RACE PCR experiments revealed a 36 nucleotide long nucleotide sequence (5 0 -GAAGACGGTTACTGACCCCGGCAATCGTTTTTTTTTT-3 0 ) fused to exon14 of the 3 0 -MLL gene. Finally, patient P05-442 displayed a 3-way-translocation involving chromosomes 1, 4 and 11, respectively. The resulting derivative chromosomes der(1), der(4) and der(11) were coding for a RABGAP1L Á MLL fusion gene (intron4Hintron11), an AF4 Á RABGAP1L fusion gene (intron3Hintron4) and the MLL Á AF4 fusion gene (intron11Hintron3), respectively. All three fusion genes represent in-frame fusions and are transcribed in the patient (Figure 2b ).
Truncated MLL and AF4 genes on derivative alleles
In three out of 10 MLL Á AF4 þ /AF4 Á MLL À patients only 3 0 -MLL or 5 0 -AF4 gene segments were identified (Figure 1 ) without any genomic fusion to another gene.
Patient P03-175 displayed a three-way-translocation involving chromosomes 2, 4 and 11, respectively. The resulting der(2) chromosome exhibits only a translocated 5 0 -MLL gene segment, while the der(4) chromosome exhibits an 5 0 -AF4 gene segment adjacent to the UNQ6975 gene. Interestingly, an inframe fusion between AF4 and UNQ6975 (exon3Hexon3) was identified at the mRNA level (Figure 2c ). The der(11) chromosome encodes the MLL Á AF4 fusion gene (intron9Hintron3).
Patient P03-187 carries an insertion of chromosome 11 material (14.1 Mbp) into the AF4 gene. This led to two genomic fusion sites on the resulting der(4) chromosome. At the centromeric fusion site only a 5 0 -AF4 gene segment was identified, while at the telomeric fusion site the MLL Á AF4 fusion gene was identified (intron9Hintron3). On the der(11) chromosome, only solitary 3 0 -MLL gene segment was identified. Finally, patient P04-275 represents a reciprocal translocation in combination with a large deletion of chromosome 4 sequences (27.2 Mbp). The der(11) chromosome displayed the MLL Á AF4 fusion (intron11Hintron3). The genomic fusion site on the der(4) chromosome involved an area located in the subcentromic area of chromosome 4q and the 3 0 -MLL gene segment.
Discussion
A panel of 76 t(4;11) leukemia patients (proB ALL) was analyzed for genomic MLL fusion alleles. For 63 t(4;11) patients t(4;11) genetics E Kowarz et al both reciprocal MLL fusion alleles were identified and sequenced (83%), while 13 patients did not display the reciprocal AF4 Á MLL fusion allele (17%). These patients were further analyzed by using LDI-PCR and LR-PCR strategies in combination with oligonucleotides specific for the 5 0 -portion of the AF4 gene, the 3 0 -portion of the MLL gene, or subsequently for the identified AF4-or MLL-fused sequences. By using this 'breakpoint hopping technique' the genetic rearrangements in 10 out of 13 patients were determined. They all displayed complex rearrangements between chromosome 4, 11 and in some cases involving a third chromosome (Figure 1 ). For the remaining three patients, the genetic situation could not be determined. We cannot exclude that these three patients also exhibit complex rearrangements, but they remained uncovered (likely owing to technical limitations of the applied LDI-PCR method).
The genetic rearrangements in these 10 t(4;11) patients revealed four different recombination mechanisms: (1) (2) and (3) represent a 'cut and paste mechanism' of chromosomal fragments into other chromosomes (see Figure 3) .
In three patients, a 3-way translocation created three independent fusion alleles. This explains why these patients were diagnosed as MLL Á AF4 þ /AF4 Á MLL À patients. Three-waytranslocations of the MLL gene were already described in two other studies. One patient with a complex rearrangement of chromosome 4, 7 and 11 carried a reciprocal CDK6 Á MLL fusion allele. 43 In a second study, conventional cytogenetics revealed a three-way translocation involving the MLL, the AF4 and a third locus on chromosome 13q34. 44 Seven out of 10 patients bear only two affected chromosomes. The reciprocal alleles represented genomic fusions between MLL and PBX1, AF4, NFkB1, FXYD6, ELF2, DSCAML1 and RABGAP1L. None of these genes has ever been described before as translocation partner gene of MLL. However, only the NFkB1 Á MLL and the RABGAP1L Á MLL fusion alleles represented in-frame gene fusions that were transcribed and able to be translated into chimeric fusion proteins (Figure 2a and b) . All other genomic fusions represented either out-of-frame, 'head-tohead' or 'tail-to-tail' gene fusions owing to the 'cut and paste mechanism'. However, no obvious MLL fusion protein could be encoded by these rearranged alleles.
In an attempt to identify chimeric transcripts for the latter alleles, 5 0 -and 3 0 -RACE experiments were performed. For the 'head-to-head' DSCAML1 Á MLL fusion allele of patient P05-403, a stretch of 36 nucleotides without any potential AUG translational start codon was fused at the RNA level to the 3 0 -MLL gene segment. However, BLAST searches revealed only similarities to short stretches of DNA derived from different chromosomes. The short nucleotide stretch was not derived from the DSCAML1 gene, neither form exonic nor from intronic sequences. In patient P03-178 the first two AF4 exons, exons1a1 and exon1a2, were fused out-of-frame to exon 10 of the MLL gene. In patient P03-175, we are able to identify an in-frame fusion between the AF4 gene (exons 1-3) and exon 3 of the downstream located UNQ6975 gene on the RNA level (Figure 2c ). This represented a 'spliced fusion', according to the recently discovered mechanism in t(11;19) patients. 45 Spliced fusions can be observed in cases where a 3 0 -truncated gene is located adjacent to an intact gene with the same transcriptional orientation. By transcriptional read-through and subsequent splicing reactions, exons of both genes can be fused together. For all other leukemia patients no RNA material was available. Therefore, we were not able to test systematically for other mRNA fusions in the remaining leukemia patients (most of the patient biopsy material was derived from retrospective studies).
Six patients exhibited either a solitary 3 0 -MLL gene segment (P03-175, P03-187, P04-275) or a 'head-to head' fusion with other genes (P03-231, P04-268, P05-403). It has been recently demonstrated that 3 0 -MLL alleles are still able to produce a shorter MLL transcript, termed MLL*. The MLL* transcript starts in front of MLL exon 12 and gives rise to an mRNA transcript that comprises MLL exon 12 until exon 37, 37 which is translated into the MLL* protein (coding for about 2.300 amino-acids of the MLL C-terminus). Thus, leukemia patients carrying either a solitary 3 0 -MLL gene segment or a 'head-to head' fusion with the 3 0 -MLL gene segment, are per se able to transcribe the MLL* mRNA. 37 The expression of the C-terminal portion of MLL has to be verified in future studies, when leukemia patients with such 0 -MLL gene segment becomes inserted into the AF4 gene; in these cases, three fusion alleles between the TPG, MLL and AF4 are being created on the resulting der(4) and der (11) chromosomes, respectively. t(4;11) genetics E Kowarz et al complex genetic alterations can be analyzed at the RNA and at the genomic DNA level in parallel. Hints for potential disease mechanisms in this particular group of t(4;11) leukemia patients may derive from our knowledge of the genes that were identified to be involved in the genetic rearrangements. PBX1 has first been identified in t(1;19) translocations, where E2A is fused in-frame to PBX1. 46, 47 Either dimeric or trimeric protein complexes of PBX1, MEIS1 and HOXA9 are binding to promoters of leukemia-associated genes, for example the FLT3 gene. 48 The balance between these factors is critical for normal hematopoietic development. The haploinsufficient situation in case of the non-functional PBX1 fusion alleles will presumably cause a shift towards HOXA9/ MEIS1 complexes, which in turn will lead to a developmental arrest of myeloid progenitors.
A similar situation can be predicted for the 'head-to-head' fusion between 3 0 -ELF2 and 3 0 -MLL. Wild-type ELF2 protein is directly binding to the runt homology domain of AML1. Binding of ELF2 to AML1 strongly transactivates the AML1 protein complex. 49 Thus, the disruption of one ELF2 allele is presumably compromising AML1 functions due to gene dosage effects, and thus, mimics an AML1 translocation because of the ELF2 haploinsufficiency (AML1 translocations, for example AML1 Á ETO, are converting the AML1 transcriptional activator into a constitutive transcriptional repressor).
50
NFkB1 is known to be constitutively overexpressed in various subtypes of ALL 51 and AML. 52 One of the two NFkB1 fusion proteins, the NFkB1 Á MLL fusion protein, will potentially interfere with normal cellular functions. This fusion protein encodes exons 1-23 of the NFkB1 gene fused to the C-terminal exons of the MLL gene. Thus, the DNA-binding domain of the rel-family transcription factor NFkB1 is fused to the enzymatic domains of MLL. This may result in ectopic gene expression of NFkB1 target genes, The reciprocal AF4 Á NFkB1 fusion protein is coding only for the first three exons of AF4 and the last exon 24 of the NFkB1 gene. This fusion is highly similar to the FelC protein. Thus, the AF4 Á NFkB1 fusion protein may have a similar function as the FelC protein, which is able to bind to SIAH1 and SIAH2, and so, lead to the retention of the two E3-ligases in the cytoplasm. This protects the AF4 fulllength protein that is localized in the nucleus against proteasomal degradation.
34
The RABGAP1L protein is a GTPase activating protein that is specifically expressed in hematopoietic cells. Both DCSAML1 and FXYD6 are also expressed in hematopoietic cells, however, their biological function is yet unknown.
In conclusion, the analysis of reciprocal alleles in MLL Á AF4 þ /AF4 Á MLL À patients revealed several novelties: (1) complex genetic rearrangements are able to masque the presence of reciprocal MLL alleles; (2) completely novel genesnot yet identified as MLL translocation partner genes -were identified as reciprocal fusion partners for the 3 0 -portion of the MLL gene (e.g. NFkB1 and RABGAP1L); (3) several genes expressed in hematopoietic cells were disrupted owing to the 'cut and paste' recombination mechanism (e.g. PBX1, FXYD6, ELF2, DSCAML1); (4) solitary 3 0 -MLL gene segments -able to express the C-terminal portion of the MLL protein -may still remain on one of the resulting derivative chromosomes. The results of this study extends our current knowledge on molecular mechanism involving the human MLL gene in acute leukemia patients, especially for t(4;11) leukemia. In most cases, a 'cut and paste' recombination mechanism makes it nearly impossible to identify the reciprocal allele by standard diagnostic procedures. Therefore, any future analysis should involve cytogenetic and RT-PCR experiments in combination with the analysis of genomic breakpoints to identify patients with complex MLL rearrangements.
Currently, there are no biological data available that would allow to draw any conclusion on the biology of these patients. Therefore, we would like to invite potential collaborators to analyze this group of MLL Á AF4 þ /AF4 Á MLL À leukemia patients in more detail. Besides the genotypic analysis at the RNA and genomic DNA level, we suggest to use gene expression profiling experiments in combination with patient treatment data (treatment response, outcome, etc.) to subclassify this t(4;11) patient subgroup. This may help to understand differences in leukemogenic processes and will allow us to identify interesting targets for the development of novel therapeutic strategies.
